Selected article for: "calpain inhibitor and enzymatic inhibition"

Author: Chunlong Ma; Brett Hurst; Yanmei Hu; Tommy Szeto; Bart Tarbet; Jun Wang
Title: Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
  • Document date: 2020_4_20
  • ID: 047xpt2c_14
    Snippet: To test the hypothesis that inhibiting the enzymatic activity of M pro will lead to the inhibition of SARS-CoV-2 viral replication, we performed cellular antiviral assays for the five promising hits 64, 28, 43, 61, and 62 against SARS-CoV-2. For this, we first tested the cellular cytotoxicity of these compounds in multiple cell lines (Table 3) . GC-376 (64), boceprevir (28) , and calpain inhibitor II (61) were well tolerated and had CC50 values o.....
    Document: To test the hypothesis that inhibiting the enzymatic activity of M pro will lead to the inhibition of SARS-CoV-2 viral replication, we performed cellular antiviral assays for the five promising hits 64, 28, 43, 61, and 62 against SARS-CoV-2. For this, we first tested the cellular cytotoxicity of these compounds in multiple cell lines (Table 3) . GC-376 (64), boceprevir (28) , and calpain inhibitor II (61) were well tolerated and had CC50 values of over 100 µM for all the cell lines tested.

    Search related documents:
    Co phrase search for related documents
    • antiviral assay and cellular antiviral assay: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antiviral assay and cellular cytotoxicity: 1, 2
    • antiviral assay and enzymatic activity: 1, 2
    • antiviral assay and SARS viral replication: 1, 2, 3, 4, 5
    • antiviral assay and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • cell line and enzymatic activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • cell line and multiple cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cell line and SARS viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cell line and SARS viral replication inhibition: 1
    • cell line and test cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cell line and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cellular antiviral assay and enzymatic activity: 1
    • cellular antiviral assay and viral replication: 1, 2, 3
    • cellular cytotoxicity and viral replication: 1, 2, 3, 4, 5
    • enzymatic activity and SARS viral replication: 1, 2, 3, 4, 5, 6, 7
    • enzymatic activity and SARS viral replication inhibition: 1
    • enzymatic activity and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • multiple cell line and viral replication: 1
    • promising hit and SARS viral replication: 1, 2